Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Kevin Koch
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 127
- Beta
- 0.28
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 82.39
Financials
Net Income
$-57.33MEBITDA
$-56.79MFree Cash Flow
$-43.54MEPS (diluted)
$-0.53Shares Outstanding (diluted)
107.67M+429.4%Operating Expenses
$61.94MCash & Debt
$460.71MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-167.79M | $-1.63 |
| 2024 | $0.00 | $-133.81M | $-1.45 |
| 2023 | $0.00 | $-100.16M | $-1.57 |
| 2022 | $0.00 | $-67.64M | $-1.26 |
| 2021 | $0.00 | $-42.81M | $-0.86 |
| 2020 | $0.00 | $-17.05M | $-0.35 |
| 2019 | $0.00 | $-9.49M | $-0.19 |
Valuation
EWTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
163+1533.33%Social Signal Score
Mentions (6)
- News (RSS)seekingalpha·13d ago·Positive
Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript
View source ↗ - Newsseekingalpha.com·13d ago·Positive
Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript
View source ↗ - Newsprnewswire.com·14d ago·Neutral
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500 - The MoA that targets the Regulatory Light Chain (RLC) has shown in preclinical models to improve cardiac relaxation while preserving systolic function and cardiac reserve - - Company to host webcast to discuss these findings today at 8:30 a.m. Eastern Time - BOULDER, Colo.
View source ↗ - News (RSS)investing·18d ago·Neutral
Edgewise Therapeutics stock hits all-time high at 48.41 USD
View source ↗ - Newsprnewswire.com·43d ago·Positive
…ith EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) – BOULDER, Colo., Aug. 24, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that the CIRRUS-HCM abstract was selected for a late-breaking science presentation at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany.
View source ↗ - Newsseekingalpha.com·48d ago·Negative
Edgewise Therapeutics: The Servier Deal Creates A Self-Funded Cardiovascular Platform Edgewise Therapeutics (EWTX) has transformed into a well-capitalized cardiovascular drug developer following the $1.55B sale of sevasemten to Servier. EDG-7500, EWTX's lead asset, demonstrated robust Phase 2 efficacy in both obstructive and nonobstructive HCM, with a differentiated safety and workflow profile. EWTX's cash runway now extends into the early 2030s, enabling late-stage pipeline advancement without …
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.55 per share
Typical surprise +2.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.53 vs $-0.47miss
- Thu, May 7$-0.46 vs $-0.50beat
- Thu, Feb 26$-0.47 vs $-0.43miss
- Thu, Nov 6$-0.39 vs $-0.40beat
- Thu, Aug 7$-0.34 vs $-0.42beat
- Thu, May 8$-0.43 vs $-0.45beat
Estimates and results for EWTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by EWTX officers and directors.
- Bought
- —
- Sold
- $17.4m
0 trades
32 trades
- Donovan Joanne M.sold
- Donovan Joanne M.sold
- Donovan Joanne M.sold
- Donovan Joanne M.sold
- Donovan Joanne M.sold
- Russell Alan Jsold
- Russell Alan Jsold
- Russell Alan Jsold
68 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in EWTX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.